Illumina Inc. ($ILMN) Stock Forecast: Up 5.6% Today

What is Illumina Inc.?

Illumina (ILMN) is a prominent player in the genomics sector, focusing on sequencing and array-based solutions for genetic analysis. The stock has shown notable volatility recently.

Why is Illumina Inc. going up?

ILMN stock is up 5.6% on Feb 24, 2026 14:55

• The positive outlook on the genomics market and the company's advancements in technology and informatics are driving the bullish movement in Illumina's stock today.
• Illumina's pivotal role in genomic projects like the UK Biobank, as highlighted in an interview with Rami Mehio, underscores their expertise and contributions to the field.
• Despite recent insider selling by SVP Patricia Leckman, investors remain confident due to the company's aggressive share buybacks and robust financial health score.
• Anticipated growth in the global genomics market and Illumina's potential revenue expansion through acquisitions like SomaLogic are likely factors boosting investor optimism and contributing to the current bullish trend.

ILMN Price Chart

ILMN Technical Analysis

ILMN News

Pioneering Genomic Progress: An Interview with Rami Mehio, Illumina's Software and Informatics Expert

Rami Mehio, Head of Software and Informatics at Illumina, discusses Illumina's crucial role in the UK Biobank's whole genome sequencing project, highlighting their contributions in sequencing technology and bioinformatics using DRAGEN and ICA cloud platform. He elaborates on the challenges of analyzing 500,000 genomes, such as computational infrastructure and data aggregation, and how Illumina's technology improved variant identification and data compatibility. The interview also touches on the broader implications of these advancements for precision medicine, drug discovery, and the importance of collaboration in genomic research.

https://www.news-medical.net/news/20240115/Pioneering-Genomic-Progress-An-Interview-with-Rami-Mehio-Illuminas-Software-and-Informatics-Expert.aspx

Genomics Market Size To Hit USD 157.47 Billion By 2033

The global genomics market is projected to grow significantly from USD 33.90 billion in 2023 to USD 157.47 billion by 2033, driven by increasing demand for novel therapeutic and research applications, technological advancements, and supportive government funding. Key drivers include personalized medicine, falling sequencing costs, and growing applications in understanding and treating genetic disorders and diseases like cancer. Challenges persist in managing and securely storing the vast amounts of generated genomic data.

https://www.biospace.com/genomics-market-size-to-hit-usd-157-47-billion-by-2033

Shareholders in Illumina (NASDAQ:ILMN) have lost 77%, as stock drops 6.8% this past week

Illumina (NASDAQ:ILMN) shareholders have experienced significant losses, with the stock plunging 78% over the last three years and 42% in the past year. The recent 6.8% drop adds to the concern, raising questions about the company's long-term stock performance despite maintaining top-line revenue and paying dividends. While the company has been profitable in the past, its current trailing twelve-month loss suggests an inconsistent profit record.

https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-ilmn/illumina/news/shareholders-in-illumina-nasdaqilmn-have-lost-77-as-stock-dr

Illumina SVP Leckman sells $275k in stock

Patricia Leckman, SVP and Chief People Officer at Illumina, sold 2,370 shares of common stock for $275,346 on February 18, 2026, and an additional 1,304 shares for $151,929 on February 15, 2026. Despite these insider sales, InvestingPro data indicates aggressive share buybacks by management and the company recently surpassed Q4 2025 earnings and revenue expectations. Illumina's stock has seen an 80.18% price return over the past six months and holds a "fair" financial health score.

https://au.investing.com/news/insider-trading-news/illumina-svp-leckman-sells-275k-in-stock-93CH-4265333

Illumina Stock is Down 80% From Its All-Time Highs: Can It Recover in 2026?

Illumina stock is down 80% from its all-time highs, but recent Q4 2025 earnings show promise with revenue beat and clinical consumables growth. The company completed the SomaLogic acquisition, adding proteomics, which is expected to contribute to revenue growth despite some EPS dilution and margin compression. A TIKR valuation model projects an 11% annualized return to $158 by December 2028, contingent on sustained clinical consumables momentum and successful integration of SomaLogic.

https://www.tikr.com/blog/illumina-stock-is-down-80-from-its-all-time-highs-can-it-recover-in-2026

Trending Today

Illumina Inc. Price History

20.00.2026 - ILMN Stock was up 5.1%

• The bullish movement in Illumina's stock could be attributed to the company's partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to launch the Billion Cell Atlas initiative. This ambitious project aims to map genetic perturbations in five billion human cells, providing valuable insights for drug discovery and precision medicine.
• The collaboration with major pharmaceutical companies highlights Illumina's commitment to advancing genomic research and its potential to revolutionize the field of AI-driven drug discovery.
• The emphasis on creating a comprehensive genetic dataset to accelerate drug discovery and improve target validation likely resonated positively with investors, driving the bullish market movement in Illumina's stock today.

20.00.2026 - ILMN Stock was up 5.2%

• The bullish movement in Illumina's stock today is due to Medicare's decision to cover the TruSight™ Oncology Comprehensive test, enabling a clear reimbursement pathway and broadening access to precision oncology. This development is expected to significantly boost Illumina's revenue and enhance investor confidence in the company's clinical focus.
• Illumina's collaboration with major pharmaceutical companies like AstraZeneca, Merck, and Eli Lilly on the Billion Cell Atlas initiative is a testament to its dedication to advancing drug discovery and precision medicine by mapping disease biology at an unprecedented scale. This partnership underscores Illumina's leading position in genomic research and innovation, strengthening its market presence and growth potential.
• The company's integrated genomic workflow solutions for genetic disease research, which prioritize high-quality genomic data generation and interpretation, also contribute to its positive market sentiment. Illumina's holistic approach to genetic research and emphasis on scalable informatics are resonating well with investors, fueling optimism about the company's future prospects in the genomics industry.

21.00.2026 - ILMN Stock was up 5.1%

• Illumina's stock surged today following the news of securing CMS reimbursement for its TruSight Oncology Comprehensive test at $2,989.55 per test, effective January 1, 2026. This reimbursement is expected to drive adoption of the test, boosting Illumina's market share and revenue.
• The partnership with pharma giants like AstraZeneca, Merck, and Eli Lilly to map disease biology at an unprecedented scale through the Billion Cell Atlas initiative also contributed to the bullish movement. This collaboration enhances Illumina's position in the precision medicine field and strengthens its role in accelerating drug discovery processes.
• Analysts' positive outlook on Illumina's earnings growth and target price increases from firms like TD Cowen and Guggenheim further fueled investor optimism, driving the stock higher.
• Illumina's focus on offering integrated genomic workflow solutions for genetic disease research and emphasizing scalable informatics and high-quality genomic data generation also added to the positive market sentiment, showcasing the company's commitment to innovation and advancement in the genomics industry.

06.01.2026 - ILMN Stock was down 12.3%

• Despite strong Q4 2025 earnings that surpassed expectations, Illumina's stock saw a notable decline following a cautious 2026 revenue outlook.
• Investor response suggests disappointment with the company's conservative forecast for the upcoming period, despite its previous strong performance.
• Illumina's strategic focus on core sequencing, multiomics scaling, and data/software expansion is contributing to its momentum. However, concerns around the subdued 2026 revenue guidance seemed to overshadow these accomplishments for investors.
• While the company remains optimistic about the growing adoption of sequencing-based diagnostic tests and the NovaSeq X instrument in clinical settings, these positive prospects were unable to offset worries about future growth potential, resulting in a bearish trend for the stock.

06.01.2026 - ILMN Stock was down 9.6%

• Despite surpassing Q4 earnings forecasts, Illumina's stock trended bearishly due to its conservative 2026 revenue guidance, disappointing investors who were anticipating a more aggressive outlook.
• The market's response suggests that investors are evaluating Illumina's robust operational performance in Q4 against its unchanging annual revenue for 2025, which paralleled the previous year.
• Although Illumina offered a positive forecast for 2026, anticipating revenue growth of 4-6% and adjusted EPS of $5.05-$5.20, the stock's decline indicates that investors possibly anticipated more ambitious future projections.
• The contrast between the company's solid financial performance and the market's reaction underscores the significance of managing investor expectations and articulating a compelling growth narrative for forthcoming results.

06.00.2026 - ILMN Stock was up 5.3%

• In spite of regulatory challenges and cautious sentiment from investors, Illumina demonstrated significant bullish momentum today.
• While receiving "hold" ratings from Wall Street Zen and Zacks Research, the company surpassed Q3 earnings projections and offered optimistic FY2025 guidance, resonating well with investors.
• The positive market response can be linked to hopeful investor sentiment regarding Illumina's anticipated recovery, supported by its strategic capital allocation and increasing demand for sequencing.
• Illumina's efforts to adapt to the AI era and consolidate its place in the genomics sector have instilled a sense of cautious optimism among investors and insiders about the company's future trajectory.

24.01.2026 - ILMN Stock was up 5.6%

• The positive outlook on the genomics market and the company's advancements in technology and informatics are driving the bullish movement in Illumina's stock today.
• Illumina's pivotal role in genomic projects like the UK Biobank, as highlighted in an interview with Rami Mehio, underscores their expertise and contributions to the field.
• Despite recent insider selling by SVP Patricia Leckman, investors remain confident due to the company's aggressive share buybacks and robust financial health score.
• Anticipated growth in the global genomics market and Illumina's potential revenue expansion through acquisitions like SomaLogic are likely factors boosting investor optimism and contributing to the current bullish trend.

05.10.2025 - ILMN Stock was up 5.3%

• Following the company's surpassing of its third-quarter guidance and the narrowing of its full-year revenue decline forecast, Illumina's stock rose by over 23%, indicating optimistic growth prospects.
• Investor sentiment towards Illumina turned positive, with notable investors showing confidence in the company's future performance.
• The third-quarter earnings report exceeded expectations, reporting adjusted earnings of $1.34 per share, surpassing consensus estimates and contributing to the stock's significant increase.
• Illumina's ability to outperform expectations in both earnings and revenue for the quarter ended September 2025 showcases robust operational performance and potential for further growth in the genomics sector.

31.09.2025 - ILMN Stock was up 23.9%

• Illumina's stock soared today following better-than-expected third-quarter earnings.
• The company reported adjusted earnings of $1.34 per share, exceeding the consensus of $1.17, which contributed to the bullish movement.
• Positive earnings and revenue surprises of +15.52% and +1.73%, respectively, for the quarter ended September 2025, further fueled investor confidence in Illumina's growth prospects.
• Overall, the strong financial performance and optimistic outlook from Illumina's earnings likely drove the bullish movement in the stock today.

31.09.2025 - ILMN Stock was up 25.0%

• Illumina's stock surged due to better-than-expected third-quarter earnings, with adjusted earnings surpassing consensus estimates.
• The bullish sentiment towards Illumina was further reinforced by deep-pocketed investors adopting a positive approach towards the company, as revealed by options trading data.
• The company's ability to beat both earnings and revenue estimates for the third quarter showcased its strong performance and potential for future growth, contributing to the stock's upward momentum.
• Overall, Illumina's impressive financial results and market sentiment drove the stock higher, indicating investor confidence in the company's strategic direction and growth prospects in the DNA sequencing industry.

09.11.2025 - ILMN Stock was up 3.2%

• The bullish movement of Illumina is linked to its active participation and partnerships at the 2025 CIIE, showcasing its commitment to the Chinese market and highlighting potential growth opportunities.
• The recent share price rebound and positive gains over 30 and 90 days indicate investor confidence in Illumina's future prospects, despite some fluctuations over the past year.
• Analysts' mixed views on Illumina's valuation suggest ongoing debates regarding the stock's pricing, with considerations around future growth expectations and cash flow trajectory influencing investor sentiment.

09.00.2026 - ILMN Stock was down 5.1%

• Today's bearish movement in Illumina's stock value might stem from concerns over regulatory challenges and changes in investor sentiment.
• The recent introduction of Illumina Connected Multiomics, a robust software platform for simplifying multiomic analysis in precision medicine, aimed to drive faster discovery. However, it might not have sufficiently addressed worries regarding the company's divestment plans and market demand uncertainties.
• Despite surpassing Q3 earnings expectations and offering promising FY2025 guidance, Illumina saw a downgrade to a "hold" rating by Wall Street Zen. This action could have influenced the stock's decline as investors rethought their positions.
• The anticipated rapid growth of the DNA Test Kits Market suggests a favorable industry forecast. Nevertheless, Illumina's performance might have been eclipsed by broader market dynamics and company-specific concerns.